KALA BIO Company Description

KALA BIO, Inc. a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of therapies for rare and severe eye diseases.

The company’s lead product candidates include KPI-012, which is in Phase 2b clinical trial for the treatment of persistent corneal epithelial defects; and limbal stem cell deficiency and other rare corneal diseases.

Its preclinical development product consists of KPI-014 for the treatment of rare inherited retinal diseases.

The company was formerly known as Kala Pharmaceuticals, Inc. and changed its name to KALA BIO, Inc. in August 2023.

KALA BIO, Inc. was incorporated in 2009 and is headquartered in Arlington, Massachusetts.

KALA BIO, Inc.

Country	United States
Founded	2009
Industry	Biological Products, Except Diagnostic Substances
Employees	38

Contact Details

Address: 1167 Massachusetts Avenue Arlington, Delaware 02476 United States
Phone	781 996 5252
Website	kalarx.com

Stock Details

Ticker Symbol	27F0
Exchange	Frankfurt Stock Exchange
Stock Type	Common Stock
Fiscal Year	January - December
Reporting Currency	USD
SIC Code	2836